Sunday 09, July 2017 by Jessica Combes

ADIB launches second tranche of Healthcare Pharmaceuticals Equities Basket note

 

Abu Dhabi Islamic Bank (ADIB) has launched a second tranche of its Healthcare Pharmaceuticals Equities Basket note following popular demand from customers and investors on the first tranche that was launched in May 2017.

The product provides investors with exposure to a basket of leading international companies operating across the healthcare and pharmaceutical sectors, including Pfizer, Merck, Celgene, Novartis and Novo Nordisk. The note is open for subscription until August 24, 2017 and offers a 3-month lock-in period. The minimum investment for the note, which has a maturity date of August 30, 2018, is $30,000. Designed to capitalise on projected growth in the healthcare industry, the Shari'ah-compliant note matures in one year and provides 100 per cent capital protection at maturity to minimise investment risk.

“We continue to see strong demand for ADIB’s Shari'ah-compliant equity basket notes as investors appreciate the opportunity to attain strong returns in a low return environment with no risk to their capital. Global healthcare is a growth industry due to ageing demographics in developed economies and increases in population and wealth in emerging markets. This note provides exposure to leading international pharmaceutical companies primed to capitalise on such demographic and economic trends. As a bank, we will continue to develop tailored wealth management solutions to customers which allow them to meet their financial goals through a diversified investment portfolio,” said Daffer Luqman, Global Head of Liabilities and Wealth Management at ADIB.

ADIB continues to develop and deliver best-in-class solutions tailored to meet the financial needs of customers through effective financial planning and asset allocation.

On 5 June, 2017 an ADIB Shari'ah-compliant equity note capturing the performance of blue-chip German exporters yielded 5.46 per cent upon its maturity.

 

  

Features & Analyses